SBC Medical Group Holdings Incorporated (SBC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.00%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value 194.92×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.00% | Share-based compensation / revenue. Period ending 2026-06-30. $7.85K ÷ $175.17M × 100 ≈ 0.00% |
| Interest coverage · 12 months | 194.92× | Operating income ÷ reported interest expense. $65.41M ÷ $335.57K ≈ 194.92× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 175.17M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 7.85K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 65.41M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 335.57K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $175.17M | $7.85K | $65.41M | $335.57K | (m) | 0.00% | 194.92× | Reported |
| 2026-03-31 | (m) | $169.34M | (m) | $61.00M | $256.14K | (m) | (m) | 238.17× | Reported |
| 2025-12-31 | (m) | $173.61M | $0.00 | $67.49M | $148.24K | (m) | 0.00% | 455.26× | Reported |
| 2025-09-30 | (m) | $178.46M | $215.24K | $59.36M | $107.89K | (m) | 0.12% | 550.16× | Reported |
| 2025-06-30 | (m) | $188.19M | (m) | $57.31M | $68.50K | (m) | (m) | 836.58× | Reported |
| 2025-03-31 | (m) | $197.94M | (m) | $70.04M | $29.25K | (m) | (m) | 2394.45× | Reported |
| 2024-12-31 | (m) | $205.42M | $13.02M | $70.30M | $28.30K | (m) | 6.34% | 2484.23× | Reported |
| 2024-09-30 | (m) | (m) | (m) | $17.14M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | $-1.92M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | $-1.89M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | $-1.77M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Airsculpt Technologies, Inc. (AIRS) | United States | $0.146B | -27.36 |
| LifeMD, Inc. (LFMD) | United States | $0.141B | 982.53 |
| Teladoc Health, Inc. (TDOC) | United States | $1.114B | -8.68 |